Panic disorder (PD) is characterized by panic attacks, sudden feeling of terror that strike repeatedly and without warning. Physical symptoms include chest pain, heart palpitations, sweating, trembling, shortness of breath, dizziness, abdominal discomfort, fear of losing control, fear of dying, tingling sensations, and hot flushes. Panic disorders have affected 6 million (2.7%) adult US population. Women are twice more likely to be afflicted than men. 2. Obsessive-compulsive disorder (OCD) is characterized by uncontrollable obsessions (recurring thoughts or impulses that are intrusive or inappropriate and cause the sufferer anxiety) and compulsions (repetitive behaviours or rituals). It has affected 2.2 million (1%) adult US population. It is equally common among men and women. 3. Post-traumatic stress disorder (PTSD) is characterized by persistent symptoms (nightmares, flashbacks, numbing of emotions, depression, feeling angry and irritable) that occur after experiencing a traumatic event such as war, rape, child abuse and natural disaster. It has affected 7.7 million (3.5%) adult US population. Women are more likely to be afflicted by this disorder.
INTRODUCTION

Anxiety Disorders: An Overview
Global scenario of persons afflicted by mental disorders is alarming. [1] About 500 million people suffer from neurotic, stress related and somatoform problems, 200 million from mood disorders, 83 million from mental retardation, 30 million from epilepsy, 22 million from dementia, and 16 million from schizophrenia. Anxiety disorders are serious medical illnesses that have affected 1/8 th of total population worldwide irrespective of gender, age, religion, nationality and profession. [2] Anxiety Disorders Association of America (ADAA) described anxiety disorders as the most common mental illness in the US, that have affected 19.1 million (13.3%) of the adult (18-54 years) US population. [3] A study commissioned by ADAA on 'The Economic Burden of Anxiety Disorders' revealed that anxiety disorders cost the US more than $42 billion a year, almost one-third of the $148 billion total mental health bill for the US. In India, prevalence rate for all mental disorders is 65.4 per 1000 population, and that for anxiety neurosis is 18.5 per 1000 population. [4] The Global Research on Anxiety and Depression (GRAD) network, a consortium of world's leading psychiatric epidemiologists and clinical researchers, during the 154 th annual meeting of 'American Psychiatric Association' (APA) has observed that, "a significant number of world's population is plagued by chronic and excessive anxiety, also known as generalized anxiety disorder (GAD), which is more serious than those of lung disease, sleep disorders and major depression, and affects more than 5% of the world population". [5] Following is the categories of anxiety disorders. [3, 6] In brain, Nitric oxide synthase (NOS) has been localized in regions involved with anxiety, such as hypothalamus, amygdala and hippocampus. [36, 37] Inhibition of NOS by nonselective or by relatively selective inhibitors of nNOS produced antianxietylike effect. Neurosteroids can rapidly alter the excitability of central nervous system by modulating neurotransmittergated ion channels such as GABA A and N-methyl-D-aspartate receptors. [38] Anxiolytic, anticonvulsant and anaesthetic effects of neuroactive steroids are mediated by their capacity to positively modulate GABA A receptor. 5-alpha reductase, the enzyme that converts into 5-alpha-reduced metabolites like the GABA A positive neuroactive steroid 3-alpha-hydroxy-5-alphapregnan-20-one, thus, few drugs exhibits anxiolytic action via an indirect activation of the GABA-ergic system through neuroactive steroids. [39] GABA is a major inhibitory transmitter in the central nervous system. The γ-aminobutyric acid type A (GABA A ) receptor, the chloride ion channel complex and the central benzodiazepine receptors located on the neuronal membranes within this complex have been suggested to play an important role in the regulation of the stress and anxiety states. [26, 27] The benzodiazepine binding site and GABA A receptor are structurally and functionally coupled. [28] Benzodiazepines (BZDs) have become the primary pharmacological treatment for generalized anxiety disorder. However, BZDs are often associated with tolerance development and withdrawal symptoms, which pose a risk of relapse upon discontinuation. [29, 30] Monoamine oxidase (MAO) catalyzes the oxidative deamination of a variety of monoamines such as dopamine, norepinephrine and serotonin. The MAO reaction yields aldehydes and hydrogen peroxide (H 2 O 2 ), which induces apoptosis. [31] Increased endogenous MAO inhibitory activity (tribulin activity) is associated with conditions associated with stress and anxiety, both in animals and in man. [32] Rat brain tribulin activity is significantly augmented by anxiogenic agents like pentylenetetrazole, and this effect can be prevented by anxiolytic agents. [33] Inhibition of MAO and subsequent H 2 O 2 generation effectively prevents depression and various oxidative stresses in the brain. [34] The presence of plant-derived MAO inhibitors suggests that such plant extracts could be useful as potential neuroprotectants in the treatment or prevention of depression. [ 
PLANTS HAVING ANTIANXIETY ACTIVITY
CONCLUSION
In present era, a sudden holocaust of mental disorders, and recognition of severe side effects and addiction liabilities associated with long term administration of widely prescribed synthetic drugs have aroused the attention of researchers towards natural resources. Plants like Valeriana officinalis, Nardostachys jatamansi, Withania somnifera and Panax ginseng have been used extensively in various traditional systems of therapy because of their adaptogenic and psychotropic properties. Inclusion of these well-established CNS affecting plants in the arsenal of modern therapeutics has revived the faith of researchers in the plants.
In present review article, amongst 143 plants reported to possess antianxiety activity (Table 1) :
(a) only 07 plants have been tested clinically, (b) preliminary antianxiety activity screening on crude extracts has been carried out on 90 plants. Such plants need to be explored with a view to isolate active constituents and their mode of actions, [351] (c) chemical constituents responsible for antianxiety activity have been reported in 53 plants and (d) possible mechanism of action has been reported in 41 plants.
Seven formulations of plant drugs, 02 well known classes of phytoconstitunts and 03 pure constituents present in various plants, and nutraceuticals reported to possess antianxiety activity in battery of experimental models of anxiety have been compiled in present work (Table 2) . Twelve anxiolytic formulations containing plants have been patented (Table 3) . A survey of literature revealed that 30 review articles have been published on anxiolytic plant formulations and specific plant covering broad aspects as phytochemistry, pharmacology, clinical studies, toxicology and safety profiles ( Table 4 ).
This review article would of immense help to natural product researchers to select traditionally used and clinically potential plants for their future research work.
